EFFECT OF ADHESIVE LLC CELL PRETREATMENT BY OXAMATE ON THE SURVIVAL INDEXES AFTER TRANSITION TO DE-ADHESIVE GROWTH

Authors

  • Yu. STEPANOV R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
  • D. KOLESNIK R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
  • Yu. YAKSHIBAEVA R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
  • G. SOLYANIK R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine

DOI:

https://doi.org/10.15407/exp-oncology.2024.03.237

Keywords:

oxamate, glycolysis, lactate dehydrogenase, reactive oxygen species, anchorage-independent growth, glucose consumption, lactate production, vimentin

Abstract

Background. The ability to metabolic reprogramming is a distinctive feature of metastatically active tumor cells. A classic example of metabolic reprogramming, characteristic of almost all malignant cells, is aerobic glycolysis. Therefore, inhibition of glycolysis in tumor cells is considered a promising strategy for antitumor therapy. Aim. To generate Lewis lung carcinoma (LLC) cell subpopulation after pretreatment by a lactate dehydrogenase (LDH) inhibitor — oxamate in adhesive growth conditions, and then to study the metabolism of this subpopulation in the anchorage-independent growth conditions. Materials and Methods. LLC cells were cultured without oxamate or with 17 mM oxamate in the adhesive growth conditions with the following transition to the anchorage-independent growth conditions without oxamate. A distribution of LLC cells by cell cycle phases, apoptosis rate, levels of reactive oxygen species (ROS), E-cadherin, and vimentin were determined by flow cytometry. Glucose consumption and lactate production were determined by spectrophotometry. Results. 48-h oxamate treatment in adhesive growth conditions resulted in a 30% decrease of the total number of LLC cells compared to the control. In 72 h after the transfer of both oxamate-treated and control cells into the anchorage-independent growth condition without oxamate, the number of viable cells pretreated with oxamate was reduced by 17% (p < 0.05) compared to the control cells. However, the distribution of cells by cell cycle phases did not differ. In cells pre-treated with oxamate, the rate of glucose consumption decreased by 20% (p < 0.05), ROS generation was reduced by 17%, vimentin expression decreased by 10% while the rate of lactate production was the same in oxamate-pretreated and control cells. Conclusion. The cytostatic effect of oxamate demonstrated in adhesive growth conditions persisted for 72 h in the anchorage-independent growth conditions. The absence of differences in the cell cycle phase distribution and a decrease in the ROS generation may indicate the initial stage of overcoming the cytostatic effect of oxamate after 72 h of culturing LLC cells in anchorage- independent growth conditions.

References

Weber GF. Time and circumstances: cancer cell metabolism at various stages of disease progression. Front Oncol.

;6:257. https://doi.org/10.3389/fonc.2016.00257

Ohshima K, Morii E. Metabolic reprogramming of cancer cells during tumor progression and metastasis. Metabo- lites. 2021;11:28. https://doi.org/10.3390/metabo11010028

Roda N, Gambino V, Giorgio M. Metabolic constrains rule metastasis progression. Cells. 2020;9:2081. https://doi. org/10.3390/cells9092081

Warburg O. On the origin of cancer cells. Science. 1956;123:309­314.

Vaupel P, Schmidberger H, Mayer A. The Warburg effect: essential part of metabolic reprogramming and central con­ tributor to cancer progression. Int J Radiat Biol. 2019;95:912­919. https://doi.org/10.1080/09553002.2019.1589653

Boedtkjer E, Pedersen SF. The acidic tumor microenvironment as a driver of cancer. Annu Rev Physiol. 2020;82:103­ 126. https://doi.org/10.1146/annurev­physiol­021119­034627

Gandhi N, Das GM. Metabolic reprogramming in breast cancer and its therapeutic implications. Cells. 2019;8:89. https://doi.org/10.3390/cells8020089

Nagao A, Kobayashi M, Koyasu S, et al. HIF­1­dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance. Int J Mol Sci. 2019;20:238. https://doi.org/10.3390/ijms20020238

Krieg AF, Rosenblum LJ, Henry JB. Lactate dehydrogenase isoenzymes a comparison of pyruvate­to­lactate and lac­ tate­to­pyruvate assays. Clin Chem. 1967;13:196­203.

Forkasiewicz A, Dorociak M, Stach K, et al. The usefulness of lactate dehydrogenase measurements in current onco­ logical practice. Cell Mol Biol Lett. 2020;25:35. https://doi.org/10.1186/s11658­020­00228­7

Valvona CJ, Fillmore HL, Nunn PB, et al. The regulation and function of lactate dehydrogenase A: therapeutic poten­ tial in brain tumor. Brain Pathol. 2016;26:3­17. https://doi.org/10.1111/bpa.12299

Cui J, Shi M, Xie D, et al. FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. Clin Cancer Res. 2014;10:2595­2606. https://doi.org/10.1158/1078­0432.CCR­13­2407

Shi M, Cui J, Du J, et al. A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Clin. Cancer Res. 2014;16:4370­4380. https://doi.org/10.1158/1078­0432.CCR­14­0186

Su Y, Yu Q.H, Wang XY, et al. JMJD2A promotes the Warburg effect and nasopharyngeal carcinoma progression by transactivating LDHA expression. BMC Cancer. 2017;1:477. https://doi.org/10.1186/s12885­017­3473­4

Koukourakis MI, Kakouratos C, Kalamida D, et al. Hypoxia­inducible proteins HIF1α and lactate dehydrogenase LDH5, key markers of anaerobic metabolism, relate with stem cell markers and poor post­radiotherapy outcome in bladder cancer. Int J Radiat. Biol. 2016;92:353­363. https://doi.org/10.3109/09553002.2016.1162921

Giatromanolaki A, Sivridis E, Gatter KC, et al. Tumour and Angiogenesis Research Group. Lactate dehydrogenase 5 (LDH­5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. Gynecol Oncol. 2006;103:912­918. https://doi.org/10.1016/j.ygyno.2006.05.043

Li X, Lu W, Hu Y, et al. Effective inhibition of nasopharyngeal carcinoma in vitro and in vivo by targeting glycolysis with oxamate. Int J Oncol. 2013;43:1710­1718. https://doi.org/10.3892/ijo.2013.2080

Manerba M, Di Ianni L, Govoni M, et al. Lactate dehydrogenase inhibitors can reverse inflammation induced changes in colon cancer cells. Eur J Pharm Sci. 2017;96:37­44. https://doi.org/10.1016/j.ejps.2016.09.014

Moreno­Sánchez R, Marín­Hernández Á, Del Mazo­Monsalvo I, et al. Assessment of the low inhibitory speci­ ficity of oxamate, aminooxyacetate and dichloroacetate on cancer energy metabolism. Biochim Biophys Acta. 2017;1861:3221­3236. https://doi.org/10.1016/j.bbagen.2016.08.006

Tsujino S, Shanske S, Brownell AK, et al. Molecular genetic studies of muscle lactate dehydrogenase deficiency in white patients. Ann Neurol. 1994;36:661­665. https://doi.org/10.1002/ana.410360418

Coronel­Hernández J, Salgado­García R, Cantú­De León D, et al. Combination of metformin, sodium oxamate and doxorubicin induces apoptosis and autophagy in colorectal cancer cells via downregulation HIF­1 alpha. Front Oncol. 2021;11:594200. https://doi.org/10.3389/fonc.2021.594200

Zhao Z, Han F, Yang S, et al. Oxamate­mediated inhibition of lactate dehydrogenase induces protective autophagy in gastric cancer cells: involvement of the Akt­mTOR signaling pathway. Cancer Lett. 2015;358:17­26. https://doi. org/10.1016/j.canlet.2014.11.046

Valvona CJ; Fillmore HL. Oxamate, but not selective targeting of LDH­A, inhibits medulloblastoma cell glycolysis, growth and motility. Brain Sci. 2018;8:56. https://doi.org/10.3390/brainsci8040056

Crémillieux Y, Salvati R, Dumont U, et al. H­MRS measurements of time­varying lactate production in an animal model of glioma during administration of an anti­tumoral drug. NMR Biomed. 2018;31. https://doi.org/10.1002/nbm.3861

Lu QY, Zhang L, Yee JK, et al. Metabolic consequences of LDHA inhibition by epigallocatechin gallate and oxamate in MIA PaCa­2 pancreatic cancer cells. Metabolomics. 2015;11:71­80. https://doi.org/10.1007/s11306­014­0672­8

Yang Y, Su D, Zhao L, et al. Different effects of LDH­A inhibition by oxamate in non­small cell lung cancer cells.

Oncotarget. 2014;5:11886­11896. https://doi.org/10.18632/oncotarget.2620

Mishra D, Banerjee D. Lactate dehydrogenases as metabolic links between tumor and stroma in the tumor microen­ vironment. Cancers (Basel). 2019;11:750. https://doi.org/10.3390/cancers11060750.

Downloads

Published

19.12.2024

How to Cite

STEPANOV, Y., KOLESNIK, D., YAKSHIBAEVA, Y., & SOLYANIK, G. (2024). EFFECT OF ADHESIVE LLC CELL PRETREATMENT BY OXAMATE ON THE SURVIVAL INDEXES AFTER TRANSITION TO DE-ADHESIVE GROWTH. Experimental Oncology, 46(3), 237–243. https://doi.org/10.15407/exp-oncology.2024.03.237

Issue

Section

Original contributions